

Humber Area Prescribing Committee

Date / Time	4 th September 2024 13:00- 15:00
Venue	MS Teams
Chair	Dr Sergio Raise
Notes / Action Points	Jane Morgan – Principal Pharmacist, HUTH
Quorate: Yes / No	Yes

Attendance	Dr Sergio Raise, ERY sub-locality GP Prescribing Lead (SR) Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM) Andrew Karvot – Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK) Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB) Kevin McCorry, Medicines Optimisation Pharmacist, NECS (KMc) Marian Opoku-Fofie – Deputy Chief Pharmacist – Humber Teaching NHS Foundation Trust (MOF) Natasha Suffill- Lead Clinical Pharmacist CHCP (NS) Catherine Smith- Senior Medicines Optimisation Pharmacist, NECS (CS) Daniel Newsome- Principal Pharmacist RDTTC (DN) Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH) Prof A Morice, Professor of Respiratory Medicine HUTH- (AM) Dr Narayana Pothina- Consultant in adult medicine, NLAG (NP) Joanne Goode – Chief Pharmacist Humber Health Partnership – HUTH/NLAG (JG) Dr Weeliat Chong – Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC) Dr Rolan Schreiber – Medical Secretary, Humber LMC Anna Grocholewska – Chief Pharmacist and MSO, NAVIGO
Apologies	Laura Angus- Chief Pharmacy Officer/ Director of Pharmacy and Medicines Optimisation- NHS Humber and North Yorkshire ICB (LA) Luke Storr – Senior Pharmacy Technician, HUTH (LS) Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK)

Agenda Number	Item	Discussion	Action	Lead	Due Date
2024.09.01	Apologies	Noted above			
2024.09.02	Declarations of interest	Nil			
2024.09.03	Minutes of previous meeting	Accepted as true record			
2024.09.04	Action Tracker	<p>Outstanding actions from HERPC</p> <p>Renal repatriation: November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time. December update – Not met with renal yet. March update – Updating business case. May update – to meet with NHSE August update – not yet met with NHSE September update: not yet met with NHSE October update: not yet met with NHSE November update: not yet met with NHSE December update: meeting arranged with NHSE February update: meeting arranged and business case in progress April 2024 update: JM and LA met with Paul McManus to discuss further. May 2024 update: business case ongoing July 2024 update: ongoing August 2024 update: ongoing September 2024 update: meeting with NHSE again to discuss.</p> <p>Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with Dr Ogumbambi (rheumatology lead in HUTH). Rheumatology pathway for HUTH on D&TC action tracker. To discuss at September D&TC if Dr Ogumbambi in attendance and to contact to confirm place in pathway, to enable JM to start writing paper. September update: September D&TC next week, further updates to pathway needed</p>	Ongoing	JM	10/24
			Ongoing	JM	10/24

		<p>October update: Awaiting updated pathway November update: Pathway needs further updates as new TAs published again and pharmacist who is updating has prioritised adalimumab switch. December update: ongoing February 2024 update: JG to follow up with Dr Ogumbambi March 2024 update: JG raised at HUTH D&TC; to bring NLAG RA pathway to next guideline group and invite Dr Alvi. April 2024 update: NLAG RA pathway on agenda May 2024 update: HUTH RA pathway currently circulating rheumatologists for comment. July 2024 update: HUTH RA pathway updates in progress following comments August 2024 update: updates completed and send back around rheumatologists September 2024 update: Updates still ongoing</p> <p>Feedback from Integrated Medicines Optimisation Committee</p> <p>Sodium valproate prevent compliance December 2023 –RS sent JM audit report and JM fed back to neurologists who state all their patients have annual review and forms. March 2024 update – ICB meetings with stakeholders underway. JM updating HUTH internal policy which will be shared with NLAG. April 2024 update – ICB meetings ongoing. JM meeting with HUTH team to look at internal improvements. June 2024 update – updated SCF on agenda July 2024 update – updated SCF on agenda August 2024 update – Comments from last meeting sent to CS, final version to be circulated when ready. September 2024 update – Valproate SCF on agenda, to review next month regarding inappropriate enquiries in inboxes</p> <p>Ratification of guidelines and SCFs</p> <p>To add information around initial supply of devices to erectile dysfunction following prostatectomy guidance April 2024 update: ongoing May 2024: ongoing July 2024: ongoing September 2024: information added</p> <p>Ratification of guidelines and SCFs</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p>	<p>JM/KMc</p> <p>JM</p> <p>JM</p>	<p>10/24</p> <p>4/24</p> <p>4/24</p>
--	--	---	--	-----------------------------------	--------------------------------------

		To upload erectile dysfunction following prostatectomy to website and update formulary when uploaded April 2024 update: ongoing May 2024: ongoing July 2024: ongoing September 2024: to upload Ratification of joint formulary Update joint formulary with chapter 3 Ratification of joint formulary Update joint formulary with chapter 11	Action complete Ongoing	JM/LS/AK JM/LS/AK	9/24 11/24
2024.09.05	Traffic Light Status	August 2024 TLS Dalbavancin to add to formulary as red Sitagliptin to change to first line and move alogliptin and linagliptin to second line. Chloral hydrate liquid to add to formulary as red drug	To update formulary	JM/LS/AK	10/24
2024.09.06	Feedback from Integrated Medicines Optimisation Committee	<ul style="list-style-type: none"> Migraine pathway reviewed and happy with content. However needs approval at exec and place. Anaemia pathway discussion from last month feedback. 	Noted		
2024.09.07	Work plans	<ol style="list-style-type: none"> Joint formulary alignment Shared care frameworks Guidelines 	Ongoing for information only		
2024.09.08	Ratification of joint formulary	<ul style="list-style-type: none"> Chapter 14 approved 	To update joint formulary	JM/LS/AK	10/24
2024.09.09	Ratification of guidelines and SCFs	<ol style="list-style-type: none"> Valproate SCF (ICS) – CS presented update, requires sign off by IPMOC and will be uploaded on ICS website when ready HNY ICS generic eye preparations proposal – KMc presented proposal for generic eye drop prescriptions. Within appendix with table requested as a PDF document for linking to joint formulary, awaiting confirmation where that will be hosted Atomoxetine SCF (HFT) – Approved, for 1 year expiry to enable review and a joint shared care to be prepared. Methylphenidate SCF (HFT) - Approved, for 1 year expiry to enable review and a joint shared care to be prepared. Dexamphetamine SCF (HFT) - Approved, for 1 year expiry to enable review and a joint shared care to be prepared. 	<ol style="list-style-type: none"> Approved Approved Approved and to be uploaded on APC site Approved and to be uploaded on APC site Approved and to be uploaded on APC site 	JM	10/24
2024.09.10	RDTC updates	<ul style="list-style-type: none"> July 2024 	Update formulary/red list	JM/LS/AK	

2024.09.11	Minutes from subcommittees	a) Joint formulary subcommittee (June 2027) b) Guideline subcommittee (Nil)	Attached for info only		
2024.09.12	Additional minutes for information	a) HUTH D&TC (Nil) b) HFT DTG (Nil) c) NLAG M&T (Nil) d) NYY APC (Nil)	Attached for info only		
2024.09.13	Correspondence received	Nil this month			
2024.09.14	AOB	Extensive discussions on new APC terms of reference and structure.	JM and SR to feedback request for extension to deadline to LA	JM/SR	10/24
2024.09.15	Date of next meeting	2 nd October 2024 13.00 – 15.00 Teams			